Interviews with sufferers throughout 15 US states reveal GLP-1 medicine as highly effective facilitators of weight administration, however not miracle cures, with long-term success relying on help, affordability, side-effect administration, and lowered stigma.
Study: Patient Experiences With GLP-1 Receptor Agonists. Image Credit: Yusia13 / Shutterstock
In a latest research revealed in JAMA Network Open, a bunch of researchers explored the real-world experiences, advantages, challenges, and help wants of adults utilizing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight administration and associated well being circumstances.
Background
More than one billion individuals on the planet are estimated to be residing with weight problems, a persistent situation linked to diabetes, heart problems, sleep problems, and several other cancers. The introduction of GLP-1 RAs is altering weight problems therapy by serving to individuals lose extra weight and enhance metabolism. However, many people discontinue therapy throughout the first yr, usually regaining weight afterward. While research have demonstrated the efficacy of those medicines in a scientific setting, much less is thought about how sufferers expertise them of their on a regular basis lives and methods to optimize the affected person expertise to enhance long-term therapy success. Further analysis is required to higher perceive affected person views and help wants.
About the Study
Researchers performed a small qualitative interview research involving adults from throughout the United States who have been at present utilizing or had beforehand used GLP-1 RAs for any medical indication. Participants have been recruited by ResearchMatch and snowball sampling. Interviews have been performed by video conferencing between July 22 and September 10, 2025.
Researchers interviewed 30 contributors from 15 states, together with males, ladies, and one nonbinary participant, all with various racial and ethnic backgrounds. Most contributors had kind 2 diabetes, which is essential as a result of experiences of stigma and entry have been usually formed by whether or not therapy was framed as diabetes care or weight-loss care. Topics of debate included remedy initiation, results on consuming behaviors, antagonistic results, clinician expertise and help, stigma associated to weight, and entry to therapies.
The researchers recorded, transcribed, and analyzed interviews to conduct an inductive thematic evaluation of the info. They reviewed the transcripts, developed coding methods to determine similarities and themes, assigned codes to transcripts from every interview, which have been then coded individually by two researchers, and resolved any coding discrepancies by dialogue. Themes have been added as they grew to become evident through the evaluation. The findings have been additionally evaluated by an interdisciplinary workforce of pros, together with clinicians, qualitative researchers, and a affected person who had lived expertise of utilizing GLP-1 RAs. Data saturation was judged to have been reached throughout the first 22 interviews, with an additional 8 confirming it throughout the pattern.
Study Results
The research included 30 adults with a imply age of 54 years. 23 contributors have been actively utilizing GLP-1 RAs on the time of the interview, whereas 7 had discontinued therapy because of insupportable antagonistic results, being pregnant, deterioration in kidney operate, or different access-related boundaries described within the interviews. The researchers recognized eight main themes that may very well be categorized into two primary areas: affected person experiences of advantages versus trade-offs, and the way social, scientific, and structural components have an effect on people’ experiences with GLP-1 RAs.
A typical profit shared by the vast majority of contributors was a big lower in “food noise.” This time period was utilized by people within the research to explain ongoing ideas about meals, fixed cravings for sure meals, and the endless feeling of starvation from a psychological standpoint. Compulsive consuming patterns have been additionally lowered by taking the remedy. Many contributors felt they’d been free of the necessity to frequently search for meals and subsequently had a better means to make higher meals selections.
Despite these advantages, most contributors emphasised that the remedy was not a miracle remedy. Many reported that they might help their weight reduction by making wholesome life-style modifications, reminiscent of consuming higher meals, planning their meals, and being extra lively.
Some contributors skilled solely delicate signs reminiscent of non permanent nausea, whereas others skilled extreme gastrointestinal points, together with nausea, vomiting, diarrhea, and abdomen cramps. However, some contributors discovered the delicate abdomen discomfort to be a useful reminder that they have been full and believed it was a part of the remedy working effectively.
Many contributors demonstrated a willingness to tolerate vital antagonistic results and sensible inconveniences as a result of they thought-about the weight-loss advantages worthwhile. Several described enduring disagreeable signs, navigating remedy shortages, and contacting a number of pharmacies to keep up therapy entry. Some additionally described considerations about long-term reliance on the remedy and uncertainty about what may occur after stopping therapy.
The social context surrounding therapy additionally formed affected person experiences. Participants steadily reported stigma related to utilizing weight-loss medicines. Some felt that others considered medication-assisted weight reduction as taking an “easy way out,” whereas therapy for kind 2 diabetes appeared to draw much less judgment. As a consequence, some contributors most well-liked to explain their remedy use as diabetes therapy moderately than weight problems therapy.
Some contributors praised healthcare professionals who offered clear explanations and ongoing steerage. Others reported receiving prescriptions with little sensible counseling about anticipated signs or long-term administration. Participants expressed a robust need for extra reasonable and accessible data, together with sensible steerage on antagonistic results, injection gadgets, weight-reduction plan, and follow-up care.
Affordability and lack of insurance coverage protection have been main obstacles in acquiring medicines. Several contributors described price and insurance coverage protection as main boundaries, and one participant reported stopping therapy due to competing monetary calls for. Many of these interviewed additionally mentioned peer help was important, whether or not that help got here from household, mates, or on-line communities comprised of others taking the identical remedy. They acknowledged that sharing experiences helped them really feel extra regular concerning the difficulties, offered sensible recommendation, and supplied encouragement all through therapy.
Conclusion
This research confirmed that GLP-1 RAs operate as facilitators that will assist sufferers regain management over consuming behaviors moderately than as standalone options for weight reduction. Participants described remedy as working alongside long-term life-style modifications, reminiscent of a nutritious diet and train, moderately than changing private effort. Patients reported optimistic advantages from the remedy; nevertheless, there have been destructive experiences, stigma, inconsistent steerage from the healthcare supplier, and excessive prices as boundaries to continued use of GLP-1 RAs. These boundaries underscore the necessity for complete affected person training, ongoing help from healthcare suppliers, and equitable entry to therapy.
Given that this can be a qualitative research of 30 contributors, the findings shouldn’t be interpreted as estimates of how frequent these experiences are amongst all GLP-1 RA customers. The authors additionally famous potential choice bias, as a result of individuals with particularly optimistic or destructive experiences might have been extra prone to take part.
Download your PDF copy by clicking here.
Journal reference:
- Hunt, I. de V., Ramirez-Posada, M., Babu, C. S., Brown-Johnson, C., Linos, E., & Rodriguez, F. (2026). Patient experiences with GLP-1 receptor agonists. JAMA Network Open. 9(6). DOI: 10.1001/jamanetworkopen.2026.16951.